7 results on '"Shoop-Worrall, Stephanie J.W."'
Search Results
2. Towards stratified treatment of JIA: machine learning identifies subtypes in response to methotrexate from four UK cohorts
- Author
-
Shoop-Worrall, Stephanie J.W., primary, Lawson-Tovey, Saskia, additional, Wedderburn, Lucy R., additional, Hyrich, Kimme L., additional, Geifman, Nophar, additional, Kimonyo, Aline, additional, McNeece, Alyssia, additional, Dick, Andrew, additional, Morris, Andrew, additional, Yarwood, Annie, additional, Ramanan, Athimalaipet, additional, Jebson, Bethany R., additional, Wallace, Chris, additional, Dastros-Pitei, Daniela, additional, Tarasek, Damian, additional, Ralph, Elizabeth, additional, Carlsson, Emil, additional, Robinson, Emily, additional, Sumner, Emma, additional, Merali, Fatema, additional, Dekaj, Fatjon, additional, Neale, Helen, additional, Al-Mossawi, Hussein, additional, Roberts, Jacqui, additional, Gritzfeld, Jenna F., additional, Fairlie, Joanna, additional, Bowes, John, additional, Ioannou, John, additional, Kartawinata, Melissa, additional, Tordoff, Melissa, additional, Barnes, Michael, additional, Beresford, Michael W., additional, Stadler, Michael, additional, Martin, Paul, additional, Kallala, Rami, additional, Ng, Sandra, additional, Smith, Samantha, additional, Clarke, Sarah, additional, Raychaudhuri, Soumya, additional, Shoop-Worrall, Stephanie J.W., additional, Eyre, Stephen, additional, Mukherjee, Sumanta, additional, Duerr, Teresa, additional, Sornasse, Thierry, additional, Alexiou, Vasiliki, additional, Burton, Victoria J., additional, Lin, Wei-Yu, additional, Thomson, Wendy, additional, and Wanstall, Zoe, additional
- Published
- 2024
- Full Text
- View/download PDF
3. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies:2023 update
- Author
-
Gossec, Laure, Kerschbaumer, Andreas, Ferreira, Ricardo J. O., Aletaha, Daniel, Baraliakos, Xenofon, Bertheussen, Heidi, Boehncke, Wolf-Henning, Esbensen, Bente Appel, McInnes, Iain B., McGonagle, Dennis, Winthrop, Kevin L, Balanescu, Andra, Balint, Peter V, Burmester, Gerd R., Cañete, Juan D., Claudepierre, Pascal, Eder, Lihi, Hetland, Merete Lund, Iagnocco, Annamaria, Kristensen, Lars Erik, Lories, Rik, Queiro, Rubén, Mauro, Daniele, Marzo-Ortega, Helena, Mease, Philip J., Nash, Peter, Wagenaar, Wendy, Savage, Laura, Schett, Georg, Shoop-Worrall, Stephanie J.W., Tanaka, Yoshiya, Van Den Bosch, Filip E., van der Helm-van Mil, Annette, Zabotti, Alen, van der Heijde, Désirée, Smolen, Josef S, Gossec, Laure, Kerschbaumer, Andreas, Ferreira, Ricardo J. O., Aletaha, Daniel, Baraliakos, Xenofon, Bertheussen, Heidi, Boehncke, Wolf-Henning, Esbensen, Bente Appel, McInnes, Iain B., McGonagle, Dennis, Winthrop, Kevin L, Balanescu, Andra, Balint, Peter V, Burmester, Gerd R., Cañete, Juan D., Claudepierre, Pascal, Eder, Lihi, Hetland, Merete Lund, Iagnocco, Annamaria, Kristensen, Lars Erik, Lories, Rik, Queiro, Rubén, Mauro, Daniele, Marzo-Ortega, Helena, Mease, Philip J., Nash, Peter, Wagenaar, Wendy, Savage, Laura, Schett, Georg, Shoop-Worrall, Stephanie J.W., Tanaka, Yoshiya, Van Den Bosch, Filip E., van der Helm-van Mil, Annette, Zabotti, Alen, van der Heijde, Désirée, and Smolen, Josef S
- Abstract
Objective New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. Results The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. Conclusion These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA., Objective: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. Results: The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. Conclusion: These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.
- Published
- 2024
4. COVID-19-related anxiety trajectories in children, young people and adults with rheumatic diseases
- Author
-
Research UMC Utrecht, Immuno/reuma ERN, Shoop-Worrall, Stephanie J.W., Verstappen, Suzanne M.M., Costello, Wendy, Angevare, Saskya P., Uziel, Yosef, Wouters, Carine, Wulffraat, Nico, Beesley, Richard, Research UMC Utrecht, Immuno/reuma ERN, Shoop-Worrall, Stephanie J.W., Verstappen, Suzanne M.M., Costello, Wendy, Angevare, Saskya P., Uziel, Yosef, Wouters, Carine, Wulffraat, Nico, and Beesley, Richard
- Published
- 2023
5. The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis
- Author
-
Shoop-Worrall, Stephanie J.W., primary, Moull, Louisa, additional, McDonagh, Janet E., additional, and Hyrich, Kimme L., additional
- Published
- 2022
- Full Text
- View/download PDF
6. How common is remission in juvenile idiopathic arthritis: A systematic review
- Author
-
Shoop-Worrall, Stephanie J.W., Kearsley-Fleet, Lianne, Thomson, Wendy, Verstappen, Suzanne M.M., and Hyrich, Kimme L.
- Subjects
Male ,PsA, psoriatic arthritis ,Remission ,Remission, Spontaneous ,EULAR, European League against Rheumatism ,ACR, American College of Rheumatology ,PGE, parental global evaluation ,Severity of Illness Index ,Article ,Cohort Studies ,ERA, enthesitis-related arthritis ,cJADAS, clinical JADAS ,JCA, juvenile chronic arthritis ,Humans ,Prospective Studies ,JRA, juvenile rheumatoid arthritis ,ESR, erythrocyte sedimentation rate ,PICO, Patient Intervention Comparison Outcome ,Remission Induction ,Clinically inactive disease ,JADAS, Juvenile Arthritis Disease Activity Score ,Juvenile idiopathic arthritis ,Arthritis, Juvenile ,Systematic review ,Female ,RF, rheumatoid factor ,PGA, physician’s global assessment ,QA, quality assessment ,Paediatric rheumatology - Abstract
Objectives The ideal goal of treatment for juvenile idiopathic arthritis (JIA) is disease remission. However, many sets of remission criteria have been developed and no systematic review of remission in JIA exists. The current systematic review investigated (1) how remission has been defined across JIA clinical cohorts and (2) the frequency of remission overall and within disease categories. Methods Studies using prospective inception cohorts published after 1972 were selected if they estimated remission in cohorts of ≥50 patients. Articles focusing on specific medical interventions, not defining remission clearly or not reporting disease duration at remission assessment were excluded. Studies were selected from Medline, Embase, PubMed and bibliographies of selected articles. Risks of selection, missing outcome data and outcome reporting biases were assessed. Results Within 17 studies reviewed, 88% had majority female participants and patient disease duration ranged from 0.5 to 17 years. Thirteen sets of criteria for clinically inactive disease and remission were identified. Uptake of Wallace’s preliminary criteria was good in studies recruiting or following patients after their publication (78%). Remission frequencies increased with longer disease duration from 7% within 1.5 years to 47% by 10 years following diagnosis. Patients with persistent oligoarticular and rheumatoid-factor positive polyarticular JIA were most and least likely to achieve remission, respectively. Conclusions Achievement of remission increased with longer disease duration, but many patients remain in active disease, even in contemporary cohorts. Multiple sets of outcome criteria limited comparability between studies.
- Published
- 2017
7. Predicting Remission Remains a Challenge in Patients with Juvenile Idiopathic Arthritis
- Author
-
SHOOP-WORRALL, STEPHANIE J.W., primary and HYRICH, KIMME L., additional
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.